Cerus Co. (NASDAQ:CERS) Shares Sold by Jane Street Group LLC

Jane Street Group LLC lowered its stake in Cerus Co. (NASDAQ:CERS) by 20.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 297,550 shares of the biotechnology company’s stock after selling 75,483 shares during the period. Jane Street Group LLC owned approximately 0.16% of Cerus worth $518,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CERS. Creative Planning boosted its position in Cerus by 51.3% during the third quarter. Creative Planning now owns 24,809 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 8,411 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its position in Cerus by 38.4% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 35,074 shares of the biotechnology company’s stock worth $61,000 after purchasing an additional 9,737 shares in the last quarter. Intech Investment Management LLC purchased a new stake in Cerus during the third quarter worth $71,000. Algert Global LLC purchased a new stake in Cerus during the second quarter worth $97,000. Finally, SG Americas Securities LLC purchased a new stake in Cerus during the third quarter worth $121,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus reduced their price objective on Cerus from $6.00 to $3.00 and set a “buy” rating on the stock in a research report on Thursday, October 17th.

Cerus Stock Up 7.0 %

Shares of NASDAQ:CERS opened at $1.68 on Monday. The stock’s 50-day moving average price is $1.71 and its two-hundred day moving average price is $1.89. The company has a current ratio of 2.59, a quick ratio of 1.92 and a debt-to-equity ratio of 1.19. Cerus Co. has a 12-month low of $1.38 and a 12-month high of $2.59. The firm has a market cap of $312.00 million, a price-to-earnings ratio of -15.27 and a beta of 1.24.

Insiders Place Their Bets

In other news, Director Eric Bjerkholt sold 20,000 shares of the firm’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $1.78, for a total value of $35,600.00. Following the transaction, the director now directly owns 162,133 shares in the company, valued at $288,596.74. This trade represents a 10.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.40% of the stock is owned by corporate insiders.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.